Call for Papers: World Forum on Antibody-Drug Conjugates, Targeted Radiopharmaceuticals & Theranostics (ADC-RadCon)

The organizing committee cordially invites researchers, oncologists, pharmacologists, radiochemists, and academic scholars to submit their research abstracts, clinical findings, and systematic reviews for presentation at the World Forum on Antibody-Drug Conjugates, Targeted Radiopharmaceuticals & Theranostics (ADC-RadCon), convening on April 21–22, 2027 in Paris, France (Hybrid Format).

ADC-RadCon serves as a premier international summit dedicated to advancing global innovations across antibody-drug conjugates (ADCs), targeted radionuclide therapy, precision radiopharmaceuticals, and cancer theranostics.

Key Highlights & Participant Benefits:
Global Academic Exposure: Present your research to an international assembly of leading clinical investigators, pharmaceutical developers, and academic department heads.

Official Proceedings & DOI Indexing: All accepted abstracts will be published in official conference proceedings with certified DOI indexing for institutional academic appraisal.

Educational Contact Hours: Certified professional development units provided for institutional reporting and professional compliance.

Flexible Participation: Options available for both in-person oral podium presentations in Paris and synchronous virtual streams.

Important Submission Guidelines:
Submission Deadline: February 28, 2027

Abstract Registration Due: March 18, 2027

Scope & Tracks: We welcome submissions spanning ADC design and payload technology, targeted alpha/beta emitters, molecular imaging, theranostic clinical trials, and translational oncology.

To submit your abstract or review registration tiers, please visit our official conference web portal or reach out directly to the scientific secretariat at info@adcon.catalystcolloquia.org